Ripples maintain time-locked occurrence across the septo-temporal axis and hemispheres while showing local phase coupling, revealing a dual mode of synchrony in CA1 network dynamics.

This content was first published in Golf Journal, a quarterly print and monthly digital publication exclusively for USGA Members. To be among the first to receive Golf Journal and to learn how you can ...

Publisher SEGA and developer Two Point Studios have announced Two Point Museum downloadable content “Zooseum.” A release date was not announced In this wild new downloadable content, a brand new ...

From my early days playing Roller Coaster Tycoon to now, management sims have remained in my top list of favorite genres. Yet somehow, I’ve never checked out the Two Point series until now. And Two ...

Abstract: Extracting ground points from LiDAR point clouds is essential for constructing digital terrain models (DTMs). This article presents a filtering method with strip curve fitting, based on the ...

U.S. fighter jets scrambled Wednesday to intercept four Russian warplanes off the coast of Alaska, the North American Aerospace Defense Command (NORAD) said Thursday. NORAD said in a statement it ...

U.S. fighter jets were scrambled Wednesday to identify and intercept four Russian warplanes flying near Alaska, the North American Aerospace Defense Command said in a statement. NORAD said two Russian ...

When head coach Sean Lewis took over the San Diego State football team last year, the hype centered on the team’s “Aztecs fast” offense. The hope was that it would lead to a turnaround for the program ...

While the path for any drug to go from lab research to commercialization takes years, Intercept Pharmaceuticals now stands as another example that a product’s market exit can also be long and winding.

Please provide your email address to receive an email when new articles are posted on . Intercept has voluntarily withdrawn its lone product, Ocaliva, from U.S. market for primary biliary cholangitis.

Sept 11 (Reuters) - Intercept Pharmaceuticals said on Thursday it is withdrawing its liver disease drug from the U.S. market following a request from the Food and Drug Administration. This comes as ...

After years of regulatory struggles for Intercept Pharmaceuticals and its liver disease drug Ocaliva (obeticholic acid), the FDA has called time on the drug's run in the U.S. market. The agency placed ...